Streetbeat News

Stock Prices

NRIX

Nurix Therapeutics' stock price increased following Baird's decision to maintain an Outperform rating and raise its price target from $24 to $25.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 2:17 pm

NVS

Recent unusual options activity in Novartis (NYSE:NVS) has been observed, with a bullish sentiment among high-rolling investors. Benzinga's options scanner identified 9 trades, predominantly calls, indicating expectations of a price increase for NVS shares. The activity suggests a target price window of $92.5 to $97.5. This could be a signal of privileged information, making it a critical point of interest for retail traders. Novartis's stock is slightly down with an RSI indicating it may be approaching oversold territory.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 2:17 pm

AMD

Deep-pocketed investors have shown a bearish sentiment towards Advanced Micro Devices (NASDAQ:AMD), with a notable shift in options activity. Benzinga's tracking revealed 20 extraordinary options activities, with a mix of bullish and bearish sentiments, but with a lean towards bearish at 55%. The significant options trades suggest a price target range for AMD between $125.0 to $200.0 over the next three months. The company, known for its CPUs and GPUs, recently acquired FPGA leader Xilinx, aiming to diversify its business. Currently, AMD's stock is slightly up, with an analyst from Susquehanna maintaining a positive rating and a price target of $200.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 2:16 pm

ELVN

Enliven Therapeutics shares surged following the announcement of positive proof of concept data from a Phase 1 clinical trial for ELVN-001, aimed at treating chronic myeloid leukemia.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 2:13 pm

WD

Walker & Dunlop's stock (WD) trades lower following a downgrade by Wedbush from Outperform to Neutral, with a price target reduction from $130 to $95.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 2:11 pm

LOVE

The Lovesac Company (NASDAQ:LOVE) shares dropped significantly after reporting Q4 earnings and revenue that missed analyst expectations. Earnings per share were $1.87, below the consensus of $1.93, and revenues were $250.507 million, missing the expected $265.323 million. Despite a 5% year-over-year sales increase and improved gross margins, the company's outlook for Q1 and FY25 fell short of analyst estimates, leading to a 13.97% decline in its stock price to $20.08.

Portfolio Pulse from Nabaparna Bhattacharya

April 11, 2024 | 2:08 pm

GEN

Gen Digital's stock trades lower following a downgrade by Barclays from Overweight to Equal-Weight and a reduction in the price target from $28 to $25.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 2:06 pm

KMX

CarMax CFO announced plans to open multiple off-site reconditioning and auction locations in FY26, citing wage pressures in Q4 and impacts from affordability and steep depreciation periods in recent years. However, there's an improvement in market share as of January, with a need for continued affordability improvements.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 2:04 pm

ALPN

ANAB

ELVN

JANX

RLYB

Enliven Therapeutics announced positive Phase 1 trial data for ELVN-001, causing a 26% surge in its stock. Alpine Immune Sciences saw a 36.6% jump after an acquisition agreement with Vertex. Janux Therapeutics' shares rose 16.8% amid sale considerations. Other notable movers include Rallybio Corporation with an 89.6% gain following a collaboration with Johnson & Johnson, and AnaptysBio, which rose 11.4% after an Overweight rating from Wells Fargo.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 2:01 pm

GL

Deep-pocketed investors have shown a bearish sentiment towards Globe Life (NYSE:GL), with a significant move in options trading indicating potential big changes. Benzinga's tracking revealed 38 unusual options activities, with a bearish majority (65%) through puts totaling $3,270,603 and bullish calls at $90,468. The expected price range for GL is between $90.0 and $120.0 over the next three months. Globe Life's stock is currently down by -15.4%, trading at $88.77, with an RSI suggesting it may be oversold. Analyst ratings from Evercore ISI Group, Piper Sandler, and Keefe, Bruyette & Woods average a target price of $128.33 for GL.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 2:01 pm